Evidence-based Series 7-14-2 Version 2

A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Surgical Management of Malignant Pleural Mesothelioma

Members of the Lung Cancer Disease Site Group

An assessment conducted in December 2016 deferred the review of Evidence based Series 7-14-2 Version 2, which means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol).

EBS 7-14-2 document consists of:
Section 1: Clinical Practice Guideline ENDORSED
Section 2: Systematic Review
Section 3: Guideline Development & External Review
Section 4: Document Review Summary & Tool

and is available on the CCO website on the PEBC Lung Cancer DSG page.

Release Date: May 15, 2012

For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca


Evidence-based Series 7-14-2 Version 2 ENDORSED

Surgical Management of Malignant Pleural Mesothelioma

Guideline Report History

<table>
<thead>
<tr>
<th>GUIDELINE VERSION</th>
<th>SYSTEMATIC REVIEW</th>
<th>PUBLICATIONS</th>
<th>NOTES AND KEY CHANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original version</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Version 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2012</td>
<td>2005-2012</td>
<td>New data found in Section 4: Document Review Tool</td>
<td>Updated Web publication</td>
</tr>
</tbody>
</table>

Table of Contents

Section 1: Clinical Practice Guideline ................................................................. 1
Section 2: Systematic Review .................................................................................... 6
Section 3: EBS Development Methods and External Review Process ......................... 30
Section 4: Document Review Summary and Tool .......................................................... 37
Surgical Management of Malignant Pleural Mesothelioma:
A Clinical Practice Guideline

D.E. Maziak, A. Gagliardi, A.E. Haynes, J.A. Mackay, W.K. Evans, and members of the Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care

These guideline recommendations have been ENDORSED, which means that the recommendations are still current and relevant for decision making. Please see Section 4: Document Review Summary and Tool for a summary of updated evidence published between 2005 and 2012 and for details on how this Clinical Practice Guideline was ENDORSED.

Report Date: May 15, 2012

Question

What is the role of surgery (pleurectomy or extrapleural pneumonectomy) in the treatment of adults with malignant pleural mesothelioma?

Target Population

This evidence-based series applies to adult patients with diffuse or localized malignant pleural mesothelioma.

Recommendations

Because of the lack of sufficient high-quality evidence on the surgical management of mesothelioma, the Lung Cancer Disease Site Group opinion is that:

- The role of surgery in the management of malignant pleural mesothelioma cannot be precisely defined. Specifically, the lack of randomised controlled clinical trials makes it impossible to determine whether the use of extrapleural pneumonectomy or pleurectomy improves the survival of patients with malignant pleural mesothelioma or effectively palliates the symptoms of the disease.

- In patients who undergo surgery, combined with chemotherapy and/or radiotherapy, multivariate analysis shows that longer survival is associated with small, epithelial-type, node-negative pleural mesotheliomas.

- This Evidence Summary is confined to the surgical management of malignant pleural mesothelioma. Please refer to Evidence Summary Report #7-14-1 and the Evidence-based
Series #7-14-3, to be released shortly, for opinions on the use of systemic therapy and radiation therapy in this disease.

- There is a need for future studies of the role of surgery in the treatment of mesothelioma to include evaluations of quality of life

Key Evidence

- This series is based on eighteen studies involving both extrapleural pneumonectomy and pleurectomy (eight prospective and ten retrospective), four studies examining extrapleural pneumonectomy only (two retrospective and two including both retrospective and prospective data), and twelve studies examining pleurectomy only (four prospective and eight retrospective). All but three studies also included adjuvant chemotherapy, radiotherapy or photodynamic therapy as part of the therapeutic regimen, making the assessment of the role of surgery impossible.

- Three prospective studies that involved both extrapleural pneumonectomy and pleurectomy, along with adjuvant chemotherapy, radiotherapy, or photodynamic therapy, directly compared the two surgical treatments (1-5). Longer survival was reported with pleurectomy in all three studies; however, caution must be exercised in interpreting those comparisons because the patients were not randomly allocated to the surgical procedure, and thus survival outcomes may have been influenced by pre-surgery patient characteristics.

- Operative mortality for both types of surgery was reported in two non-controlled, comparative prospective studies (3-5) and in two non-controlled, non-comparative prospective studies (6,7). Operative mortality ranged from 0% (two studies) to 3% (one study) following pleurectomy and from 4% to 14% following extrapleural pneumonectomy. In one study, operative morbidity was 5% following pleurectomy and 18% to 36% following extrapleural pneumonectomy (1); in a second study, the rates were 39% and 71%, respectively (6).

- Median survival was reported in four non-controlled, non-comparative prospective studies examining pleurectomy combined with intrapleural chemotherapy (13 to 27 patients per study) and was 9 months, 11.5 months, and 18.3 months in those four studies (8-11). Three of those studies also reported two-year survival (12% to 40%) and local recurrence rates (75% to 80%) for this combined-modality approach. Operative mortality was similar in two trials (one patient death in each study), although morbidity varied between 8% and 44% and included hemorrhage, renal toxicity, cardiac events, air leaks, and wound infections.

- Seven non-controlled prospective (1,2,4-7,12,13) and five retrospective case-series studies (14-18) explored the effect of prognostic factors on survival using multivariate analyses. Of the prospective studies, three were non-comparative studies (6,7,13), one had comparison groups that were not of interest (2), and three had relevant comparison groups but they assigned patients based on disease characteristics (1,4,5,12). Seven of those studies included treatment type as a potential prognostic variable; three specifically examined the type of surgery. The factors most commonly associated with longer survival included epithelial-type mesothelioma (five studies), earlier stage of disease (five studies), use of adjuvant or combined modality treatment (five studies), and good performance status (four studies). Factors adversely associated with survival included high pre-treatment platelet count (three studies), positive nodal status (two studies), larger preoperative tumour volume (two studies), and larger postoperative residual tumour volume (one study). The type of surgery did not have a significant impact on survival in any of the three studies that examined that association.
Two prospective and two retrospective non-comparative surgical studies, three including adjuvant chemotherapy or radiotherapy, reported the palliation of signs or symptoms of malignant mesothelioma following treatment (9,19-21). Pleural fluid control improved in 98% of 50 patients and 96% of 54 patients; the recurrence of pleural effusion was prevented in 80% of 20 patients; dyspnea improved in 47% of 20 patients and 100% of 37 patients; and pain improved in 21% of 19 patients and 85% of 71 patients. However, none of the studies described the methods of symptom assessment in detail.

Future Research
Future trials for malignant pleural mesothelioma should consist of randomized controlled trials examining extrapleural pneumonectomy for patients with good prognosis, pleurectomy for patients with poorer prognosis, pleurodesis for patients with pleural effusions, and pleurectomy versus pleurodesis for palliation of symptoms of malignant pleural mesothelioma. Quality of life as an outcome should also be included in future surgical trials involving this disease.

Related Guidelines
- PEBE Evidence Summary #7-14-1 *Chemotherapy for Mesothelioma* (posted on the CCO Web site);
- PEBE Evidence-based Series #7-14-3 *Radiotherapy for Mesothelioma* (currently under development).

**Funding**
The PEBE is supported by Cancer Care Ontario (CCO) and the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBE is editorially independent from its funding agencies.

**Copyright**
This evidence-based series is copyright by Cancer Care Ontario; the series and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

**Disclaimer**
Care has been taken in the preparation of the information contained in this document. Nonetheless, any person seeking to apply or consult the evidence-based series is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding their content or use or application and disclaims any for their application or use in any way.

For information about the PEBE and the most current version of all reports, please visit the CCO website at [http://www.cancercare.on.ca/](http://www.cancercare.on.ca/) or contact the PEBE office at: Phone: 905-527-4322 ext. 42822  Fax: 905-526-6775  E-mail: ccopgi@mcmaster.ca
REFERENCES

The following references pertain to Section 1: A Clinical Practice Guideline. They are also referenced in Section 2: A Systematic Review; the citation number of each reference within Section 2 is shown in parentheses.

16. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-


